KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Accumulated Expenses: 2018-2024

Historic Accumulated Expenses for Esperion Therapeutics (ESPR) over the last 7 years, with Dec 2024 value amounting to $19.6 million.

  • Esperion Therapeutics' Accumulated Expenses fell 3.15% to $18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year decrease of 3.15%. This contributed to the annual value of $19.6 million for FY2024, which is 21.62% down from last year.
  • According to the latest figures from FY2024, Esperion Therapeutics' Accumulated Expenses is $19.6 million, which was down 21.62% from $25.0 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Accumulated Expenses registered a high of $25.0 million during FY2023, and its lowest value of $5.4 million during FY2022.
  • Its 3-year average for Accumulated Expenses is $16.7 million, with a median of $19.6 million in 2024.
  • As far as peak fluctuations go, Esperion Therapeutics' Accumulated Expenses slumped by 56.24% in 2020, and later surged by 360.71% in 2023.
  • Esperion Therapeutics' Accumulated Expenses (Yearly) stood at $7.7 million in 2020, then dropped by 8.48% to $7.0 million in 2021, then dropped by 22.63% to $5.4 million in 2022, then spiked by 360.71% to $25.0 million in 2023, then dropped by 21.62% to $19.6 million in 2024.